Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma: a Open-label, Randomized, Controlled Phase II Clinical Trial

NCT06281886 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06281886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06281886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma: a Open-label, Randomized, Controlled Phase II Clinical Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2024
Completion date
June 25, 2026
Enrollment
170 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, esophageal squamous cell carcinoma, toxicity